{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:16:36Z","timestamp":1761822996383},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s11934-005-0033-2","type":"journal-article","created":{"date-parts":[[2007,6,5]],"date-time":"2007-06-05T18:53:34Z","timestamp":1181069614000},"page":"405-409","source":"Crossref","is-referenced-by-count":10,"title":["The q-t interval and antimuscarinic drugs"],"prefix":"10.1007","volume":"6","author":[{"given":"Roger","family":"Dmochowski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Staskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"33_CR1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMra032426","volume":"350","author":"DM Roden","year":"2004","unstructured":"Roden DM: Drug-induced prolongation of the Q-T interval. N Engl J Med 2004, 350:1013\u20131022. Excellent review of the status of drug induction of Q-T phenomena and the current status of same.","journal-title":"N Engl J Med"},{"key":"33_CR2","doi-asserted-by":"crossref","first-page":"748","DOI":"10.2165\/00003495-199040050-00008","volume":"40","author":"HD Langtree","year":"1990","unstructured":"Langtree HD, McTavish D: Terodiline: a review of its pharmacological properties and therapeutic use in the treatment of urinary incontinence. Drugs 1990, 40:748\u2013761.","journal-title":"Drugs"},{"key":"33_CR3","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/BF00265918","volume":"42","author":"DA Stewart","year":"1992","unstructured":"Stewart DA, Taylor J, Gosh S, et al.: Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval. Eur J Clin Pharmacol 1992, 42:577\u2013580.","journal-title":"Eur J Clin Pharmacol"},{"key":"33_CR4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1136\/hrt.74.1.53","volume":"74","author":"SHL Thomas","year":"1995","unstructured":"Thomas SHL, Higham PD, Hartigan-Go K, et al.: Concentration-dependent cardiotoxicity of terodiline in patients treated for urinary incontinence. Br Heart J 1995, 74:53\u201356. Analysis correlating cardiac side events with the magnitude of serum levels.","journal-title":"Br Heart J"},{"key":"33_CR5","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1136\/bmj.302.6790.1469-c","volume":"302","author":"AA McCloud","year":"1991","unstructured":"McCloud AA, Thorogood S, Barnett S: Torsade de pointes complicating treatment with terodiline. BMJ 1991, 302:1469.","journal-title":"BMJ"},{"key":"33_CR6","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/0140-6736(91)90481-4","volume":"338","author":"MJ Connolly","year":"1991","unstructured":"Connolly MJ, Astrige PG, White EG, et al.: Torsade de pointes ventricular tachycardia and terodiline. Lancet 1991, 338:344\u2013345.","journal-title":"Lancet"},{"key":"33_CR7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/01.CIR.99.4.529","volume":"99","author":"SG Priori","year":"1999","unstructured":"Priori SG, Napolitano C, Schwartz PJ: Low penetrance in the long Q-T syndrome: clinical impact. Circulation 1999, 99:529\u2013534. Consideration of the relationship between genetic constitution and development of overt cardiac dysrhythmias associated with the long Q-T syndrome.","journal-title":"Circulation"},{"key":"33_CR8","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1001\/jama.275.17.1339","volume":"275","author":"D Thompson","year":"1996","unstructured":"Thompson D, Oster G: Use of terfenadine and contraindicated drugs. JAMA 1996, 275:1339\u20131341.","journal-title":"JAMA"},{"key":"33_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11934-003-0021-3","volume":"4","author":"HS Scarpero","year":"2004","unstructured":"Scarpero HS, Dmochowski RR: Muscarinic receptors and the urinary bladder. Curr Urol Rep 2004, 4:421\u2013428.","journal-title":"Curr Urol Rep"},{"key":"33_CR10","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/096032719101000313","volume":"10","author":"S Bannerjee","year":"1991","unstructured":"Bannerjee S, Routledge Pa, Pugh S, et al.: Poisoning with oxybutynin. Hum Exp Toxicol 1991, 10:225\u2013226.","journal-title":"Hum Exp Toxicol"},{"key":"33_CR11","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1046\/j.1532-5415.2002.50017.x","volume":"50","author":"PS Wang","year":"2002","unstructured":"Wang PS, Levin R, Zhao S, Avorn J: Urinary antispasmodic use and the risks of ventricular arrhythmia and sudden death in older patients. J Am Geriatr Soc 2002, 50:117\u2013124. Epidemiologic analysis of medication ingestion and cardiac events, considering the antimuscarinics, antihistamines, and concomitant administration of drugs with hepatic cytochrome activity.","journal-title":"J Am Geriatr Soc"},{"key":"33_CR12","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1124\/jpet.103.062182","volume":"308","author":"J Kang","year":"2005","unstructured":"Kang J, Chen XL, Wang H, et al.: Cardiac ion channel effects of tolterodine. J Pharmacol Exp Ther 2005, 308:935\u2013940.","journal-title":"J Pharmacol Exp Ther"},{"key":"33_CR13","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/sj.bjp.0703595","volume":"131","author":"SE Jones","year":"2000","unstructured":"Jones SE, Shuba LM, Zhabyeyev P, et al.: Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials. Br J Pharmacol 2000, 131:245\u2013254.","journal-title":"Br J Pharmacol"},{"key":"33_CR14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2125.1996.tb00161.x","volume":"41","author":"RM Hussain","year":"1996","unstructured":"Hussain RM, Hartigan-Go K, Thomas SH, et al.: Effect of oxybutynin on the QTc interval in elderly patients with urinary incontinence. Br J Clin Pharmacol 1996, 41:73\u201375.","journal-title":"Br J Clin Pharmacol"},{"key":"33_CR15","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1097\/00005344-200002000-00024","volume":"35","author":"SE Jones","year":"2000","unstructured":"Jones SE, Kasamaki Y, Shuba LM, et al.: Analysis of the electrophysiologic effects of short-term oxybutynin on guinea pig and rabbit ventricular cells. J Cardiovasc Pharmacol 2000, 35:334\u2013340.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"suppl 6A","key":"33_CR16","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","volume":"50","author":"RA Appell","year":"1997","unstructured":"Appell RA: Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. Urology 1997, 50(suppl 6A):90\u201396. Review of all of the clinical safety information associated with tolterodine.","journal-title":"Urology"},{"key":"33_CR17","unstructured":"Enablex Prescribing Information. http\/\/www. novartis.com. Accessed August 19, 2005."},{"key":"33_CR18","unstructured":"Vesicare Prescribing Information. http\/\/www.astellis.com. Accessed August 19, 2005."},{"key":"33_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00210-002-0554-x","volume":"366","author":"K Ikeda","year":"2002","unstructured":"Ikeda K, Kobayashi S, Suzuki M, et al.: M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol 2002, 366:97\u2013103.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"33_CR20","unstructured":"Sanctura Prescribing Information. http\/\/www.indevus.com. Accessed August 19, 2005."}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-005-0033-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-005-0033-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-005-0033-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-005-0033-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T11:55:20Z","timestamp":1652615720000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-005-0033-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["33"],"URL":"https:\/\/doi.org\/10.1007\/s11934-005-0033-2","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}